Introduction
By the end of 2019, several patients were diagnosed with pneumonia of unknown reason, epidemiologically associated with a same seafood market in Wuhan, Hubei province, central Coronaviridae, which can cause various disease with enteric, respiratory, hepatic and neurological symptoms 3 . The new coronavirus denoted as the 2019 novel coronavirus (2019-nCoV) or coronavirus disease 2019(COVID-19) quickly becomes of tremendous worldwide concern. It leads to a significant outbreak in many regions in China and expands globally, including Asia, Europe, North America, South America, Africa and Oceania. The disease is potentially zoonotic with estimated 2-5% mortality rate.
Person-to-person transmission may occur through contact and respiratory transmission or probable fecal-oral route. Currently, the number of ascertained infection cases has been daily increasing, but there is no definite treatment for the pneumonia although some potential drugs are under investigation. For the last two decades, the outbreaks of coronaviruses and intermittent worldwide public health emergences remind us that CoVs are still a severe global 6 health threat which can't be ignored. According to the latest research, useful information needed urgently for the control of the disease is highly essential.
Virology
Coronaviruses (CoVs) are named for the crown-like (or corona in Latin) spikes of the virus protruding to the periphery with a diameter of 60-160nm under electron microscopy.
Each particle is enveloped containing a single-stranded positive-sense RNA (+ssRNA) genome of 27-32 kb with 5'-cap structure and 3'-poly A tail which interacts with the nucleoprotein. All these coronaviruses have similarities in the organization as well as expression of the genome, and the genome size of CoV is largest among all RNA viruses. 16 nonstructural proteins (nsp1 to nsp16), encoded by open reading frame (ORF) 1a/b at the 5' end, are followed by the structural proteins Nucleocapsid (N), Spike (S), Envelope (E), and Membrane (M), which are encoded by other ORFs at the 3'end 4 . The envelope includes three proteins: M protein binds nucleocapsids and enhances viral assembly and budding; E protein is involved in viral morphogenesis, release as well as pathogenesis. And S protein contributes to homotrimeric spikes which recognize the receptor of the cell, thus helping virus invade target cells 5 . Since the outbreaks of SARS in 2002 and the MERS in 2012, the possibility of CoVs transmission from animals to human has been proved. CoVs are ubiquitous pathogens in nature for human and animals, usually causing gastrointestinal and respiratory infections, sometimes involving important organs such as liver, kidney, heart and brain. Sensitive to ultraviolet rays and heat. Lipid solvents such as ether, 75% ethanol, chlorine-containing disinfectant, peracetic acid, and chloroform can effectively inactivate the virus.
Coronaviruses consist of the largest group belonging to the Nidovirales order, which 7 contains Coronaviridae, Arteriviridae, and Roniviridae families. The family Coronaviridae is composed of large, single, plus-stranded RNA viruses which are isolated from several species and previously known to induce common colds and diarrheal illnesses in humans 5 .
The Coronavirinae is one of two subfamilies in the Coronaviridae family, and the other one is the Torovirinae. The Coronavirinae is further subdivided into four groups, the alpha, beta, gamma and delta coronaviruses. The viruses were sorted into the groups according to serology initially but are now labelled by phylogenetic clustering 6 . Only alpha and beta coronavirus are of interest for human and clinical virologists 7 . Based on epidemiological data before 2019, only six CoVs proved to cause human respiratory diseases: i) HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E only lead to mild upper respiratory disease, but rarely bring about severe diseases in people; ii) SARS-CoV and MERS-CoV attack lower respiratory tract and always induce severe respiratory syndrome. Sequence analysis shows that 2019-nCoV has a typical genome structure of coronavirus and belongs to the cluster of beta coronaviruses that includes SARS-CoV and MERS-CoV and it forms a clade within the subgenus Sarbecovirus, Orthocoronavirinae subfamily. It has been the seventh member of the family of coronaviruses that infect humans so far 8 .
Potiential hosts
Evolutionary models and phylogenetic analysis deserve attention for helping estimate genetic variability and the evolutionary rate so that in turn to provide important implications for disease progression, drug trial and vaccine development. Zhou et al. 2 report the full-length genome sequences acquired from patients at the early outbreak are almost identical to each other and shared 79.5% sequence similar to SARS-CoV. In addition, 2019-nCoV is 96% 8 identical at the whole genome level to a bat coronavirus. Wu et al. 1 almost simultaneously and independently discover the novel RNA virus from the family Coronaviridae. Phylogenetic analysis of the complete viral genome reveals that the coronavirus is most closely related (89.1% nucleotide similarity) to a group of SARS-like coronaviruses previously sampled from bats in China. Benvenuto et al. 9 bat-CoV RaTG13 sequence throughout the genome (similarity 96.3%). The latter does not provide the exact variant that caused the outbreak in humans, but the hypothesis that 2019-nCoV has originated from bats is possible. Xu et al. 12 also report that the 2019-nCoV shares with the SARS/SARS-like coronaviruses a common ancestor that relates to the bat coronavirus HKU9-1. They conclude that the 2019-nCoV S protein and SARS-CoV S protein share an almost identical 3-D structure in the RBD domain, thus maintaining similar van der 9 Waals and electrostatic properties in the interaction interface of human ACE2 molecules despite the sequence diversity。 Although many scientists believe that bats are intermediate hosts, most species of bats live in tropical or subtropical rain forests and caves far from the population, the probability of bats transmitting the virus directly to humans is not enough. It is generally known that bats may deliver the viruses to intermediate hosts such as wild animals or livestock, then the viruses are transmitted to humans by these intermediate hosts. Ji et al. 13 carry out using relative synonymous codon usage (RSCU) bias among different animal species. The result suggests that the 2019-nCoV appears to be a recombinant virus between the bat coronavirus and an origin-unknown coronavirus. They analyze that snake is a most probable wildlife animal reservoir, but the conclusion is controversial. Guo et al. 14 
Clinical manifestation
More than 80,000 cases have been confirmed as of February 21, 2020, and most of them had a history of close contact with the epidemic area in Wuhan or confirmed patients. Major initial symptoms include fever, most of which are high fevers that occur within several days and are not alleviated by routine anti-infective drugs, additionally coughing, headache and muscle pain or fatigue 15 . Other clinical symptoms observed at low frequency include elevated troponin levels, diarrhea, myalgia and myocarditis 15 . It should be emphasized that some asymptomatic patient are diagnosed as 2019-nCoV 16 , so the presence of asymptomatic carriers requires due attention. Nearly 20% of the patients appeared comorbidities with regard to the dysfunction of other organs, primarily renal impairment and patients with underlying cardiovascular diseases often demonstrated comorbid heart failure 13 . They gradually develop initial symptoms in the cardiovascular system, digestive system, and nervous system, which increased the difficulty of diagnosis 15 . The median interval from the start of initial symptoms to significant symptom aggravation like dyspnea or appearance of acute respiratory distress syndrome is 7 days, ranging from 1 day to 20 days, which was consistent with previous reports 13 . According to the newly released pneumonitis diagnosis and treatment plan for new coronavirus infection, severe patients often have dyspnea and/or hypoxemia one week after the onset of the illness. Serious cases can quickly progress to acute respiratory distress syndrome, septic shock, irreformable metabolic acidosis, coagulopathy and multiple organ failure. Nearly 80% of the patients have normal or decreased white blood cell counts, and 72.3% hav lymphocytopenia 15 . Lung involvement was present in all cases 17, 18 , with most chest computed tomography (CT) scans showing lesions in multiple lung lobes, some of which are dense. Ground-glass opacity co-existed with consolidation shadows or cord-like shadows are observed. Since respiratory supports are administered to most of the patients, oxygen saturation can be maintained at above 90% as indicated by pulse oximetry monitoring 15 . It is reported that severe and critically ill patients have moderate to low fever, even without obvious fever. Mild patients show just low fever, mild fatigue, and no pneumonia. Judging from the current cases, most patients have a good prognosis but poor for the elderly and those with chronic underlying disease. Symptoms in children are relatively mild.
As for the current situation, the source of infection is mainly the infected patients, 
Detection

General examination
Mild patients may not have positive signs, while severe patients may have shortness of breath with moist rales of both lungs, weakened breath sounds, dullness percussion, enhanced or weakened vocal fremitus palpation 20 .
Chest imaging examination
Suspected or confirmed cases should undertake chest X-ray examination as early as possible and chest CT scan is required when necessary 21 . In the early phase of the disease, chest images show interstitial changes and multiple small plaques, especially in the lung periphery. Then the changes further deteriorate to the bilateral and are mainly distributed in the middle and outer zones of the lung with multiple infiltrating shadows and/or ground-glass opacity. Patients may have a single lobe or multiple lobes involved. When the condition gets better, a little fibrous stripe may appear 22 . Conversely, lung consolidation may occur in severe cases whose pleural effusions are rarely seen.
Laboratory examination 4.3.1 Hematologic examination
At the early stage, white blood cell counts are normal or decreased, with decreased lymphocyte counts. If the absolute value of lymphocyte is less than 0.8×10 9 /L, or the CD4 and CD8 T cell counts are significantly decreased, it needs high attention. It is generally recommended to recheck the blood routine changes after 3 days 20 . In some patients, muscle enzymes, liver enzymes, and myohemoglobin levels are increased. Otherwise, the troponin is increased in some critical patients. Most patients display elevated erythrocyte sedimentation rate and C-reactive protein level, and normal procalcitonin levels. Severe cases show progressively decreased blood lymphocytes counts and high D-dimer levels. Inflammatory factors are often increased in severe and critical patients.
Molecular diagnosis
RT-PCR Samples of suspected 2019-nCoV patients collected from the upper respiratory tract (nasopharyngeal and oropharyngeal), the lower respiratory tract (expectorated sputum, endotracheal aspirate, or bronchoalveolar lavage), blood and feces can be diagnosed by real time reverse-transcription-polymerase chain-reaction (RT-PCR) 23 . Two sequence regions (ORF1b and N) designed based on the first public access sequence in Genbank are selected for primer and probe designs, which are highly conserved amongst Sarbecoviruses. In detecting positive clinical specimens, the N gene assay is about 10 times more sensitive than the ORF-1b gene assay 24 
Pathogenic mechanism
Lu et al. 13 sequence the 2019-nCoV and phylogenetic analysis reveals that the 2019-nCoV belonged to beta coronaviruses with 79.0% nucleotide identity to SARS-CoV and 51.8% identity to MERS-CoV which means 2019-nCoV is closer to SARS-CoV than MERS-CoV. Importantly, the homology modelling revealed that the receptor-binding domain structure of 2019-nCoV is similar to that of SARS-CoV 21 . From the previous reports, the interaction with Angiotensin Converting Enzyme 2 (ACE2) is responsible for SARS-CoV entering human cells 27, 28 . Dong et al. 29 compare the structural similarity of the protein ACE2 in various viruses and speculate that the 2019-nCoV could most likely use the same receptor as SARS-CoV. Zhou et al. 30 conduct virus infectivity studies using Hela cells with or without ACE2 proteins obtained from humans or animals and find that 2019-nCoV can invade all ACE2 protein-expressing cells but the cells from mouse. In short, 2019-nCoV uses ACE2 as an entry receptor in the ACE2-expressing cells, but not cells without ACE2, and 2019-nCoV is likely to bind to ACE2 receptor in humans just like SARS-CoV. Dimitrov et al. 31 reported that SARS-CoV infects the host cells in human by a basic interaction of its S glycoprotein and the receptor ACE2 on human cells. Though the sequence of 2019-nCoV is a little different from the SARS-CoV, its functionally important ORFs and major structural proteins especially the Spike protein are well annotated, of which the original identity is 76% 32 . The S protein has two regions, S2 and S1, which holds stronger affinity with the receptor binding domain (RBD) in the S1 region interacting with ACE2 24 . Similar to SARS-CoV, the 2019-nCoV may also engage the RBD to bind ACE2 in order to enter the human host cells, but since many residues 16 in S1 and S2 have been replaced in 2019-nCoV, the differences in the interactions with ACE2 on host cells exist 29, 33 . Daniel et al. 34 
However, if the SARS-CoV trys to invade the host cells, it's not as simple as ACE2
interacting with S protein for some pathways and cytokine included. Chemokine (C-C motif) ligand 2 (CCL2) is an important cytokine in Spike-ACE2 signaling pathway. CCL2 is a CC chemokine and it attracts memory T lymphocytes, monocytes and basophils. The receptor of CCL2 is CCR2, both of which are involved in inflammatory reaction 35 , therefore they are associated with some lung inflammatory disorders. Referring to previous reports, the patients who infect SARS-CoV would have pulmonary fibrosis which is responsible to CCL2. Cheung et al. 36 take an experiment to observe the expression of CCL2 in SARS-CoV patients and they find the expression of CCL2 is upregulation in the sera of patients. To work out the relationship between Spike-ACE2 signaling pathway and CCL2, Chen et al. 37 get a conclusion and showed it in Fig 2 showing the interaction between S protein of SARS-CoV with ACE2 on the human cells. The infected lung epithelial cells induce casein kinase II (CK II) which is able to phosphorylate ACE2 and involves ERK1/2 activation. CK II phosphorylates ACE2 at Ser-787, by which SARS-CoV binds to its ACE2 receptor and causes the conformational change of ACE2. It also activates the ACE2 downstream signal transduction pathways including ERK1/2 and AP-1 38 . The change will lead to the activation of ERK1/2 and AP-1 and upregulates CCL2. ACE2 also participates in an intracellular signaling pathway. It activates ERK1/2 via interacting with upstream factors such as Ras, and PKC. In the end, the elevated level of CCL2 protein in the sera of SARS-CoV-infected patients accounts for the development of lung fibrosis.
Therapeutic target
2019-nCoV is characterized by strong contagion, high morbidity and high mortality, but no specific drugs of 2019-nCoV have been developed so far. Many researchers are trying to find the therapeutic targets of the virus to work out high-efficiency and low toxicity targeted drugs. A number of epidemiological studies have shown that the transmission characteristics of 2019-nCoV appear to be a similar of SARS [39] [40] [41] [42] . The series of similarities give doctors and scientists a clue to look for targeted drugs. Although coronaviruses are subject to extensive mutations, some key proteins, particularly replication-related enzymes, are highly conserved 2 , so the drugs that target conserved proteases are usually able to block replication and proliferation of the virus and exhibit a broad spectrum 22 . Specific inhibitors of key proteases involved in viral replication and proliferation are effective ways of killing viruses. Candidate compounds include RNA proteases, membrane proteins, spike glycoproteins, polymerases, and viral envelope that act directly on the virus, as well as targets on the host, such as receptors and proteases for virus entry and endocytosis 24, 43, 44 . Recently, scientists screen out 4 small molecule drugs (Prulifloxacin, Tegobuvir, Nelfinavir and Bictegravir) with strong binding ability to the main protease of SARS-CoV 22 . The first case of the 2019-nCoV infected pneumonia in the United States experienced significant improvement in clinical symptoms after receiving an intravenous infusion of Remdesivir on the seventh day of hospitalization 45 .
Remdesivir is a novel nucleotide analogue prodrug under development that inhibits viruses by inhibiting RNA-derived RNA polymerase (RdRp), which was originally used to treat Ebola but didn't work. Amazingly, it is effective against SARS and MERS. [46] [47] [48] [49] In addition to this, 2019-nCoV is unable to infect cells without ACE2 and cannot bind to other common receptors of coronavirus (APN, DPP4, etc.) 2, 8, 50 . After replacing four out of five important interface amino acid residues, 2019-nCoV S protein maintains the core structure and interacts perfectly with human ACE2 molecule 12 . These studies show that ACE2 targeted drugs are expected to be used to treat 2019-nCoV. The S2 subunit of SARS-CoV spike protein plays a key role in mediating the fusion of virus and host cell and entering the host cell. Heptapeptide repeat 1 (HR1) and heptapeptide repeat 2 (HR2) can interact to form six helix bundles (6Hb), which makes the virus and cell membrane tightly bound 51 . A variety of effective fusion inhibitors against SARS coronavirus and Middle East respiratory syndrome (MERS) coronavirus have been developed by using S-HR1 and S-HR2，such as HR2P peptide 52 . Researchers have found that the HR1 and HR2 regions of the 2019-ncov could also interact to form 6hbs, and they have designed a pan-coronavirus fusion inhibitor denoted as EK1, which can significantly inhibit 2019-nCoV pseudo virus infection in a dose-dependent manner 53 . 19 
Treatment strategy
Antiviral therapy
At present, different institutions and organizations in China have issued several guidelines for the diagnosis and treatment of novel coronavirus pneumonia, none of which pointed out specific drugs for 2019-nCoV. According to the latest treatment protocol (Pilot Version 6) issued by the Chinese health commission, antiviral therapy can be tried with interferon, lopinavir/litonavir, chloroquine phosphate and arbidol. These drugs and other potentially effective drugs are described here.
Nucleoside analogs
Remdesivir is a nucleoside analogue with antiviral activity developed by Gilead Scientific. Its anti-RNA virus activity has been confirme, such as Ebola, Marburg virus, Nipa virus, Hendra virus [54] [55] [56] . What's more, Remdesivir has exhibited preventive and therapeutic effects on MERS-CoV and SARS-CoV in vitro 57, 58 . Remdesivi is detected to have the ability to reduce MERS-CoV, improve pulmonary function and reduce lesions of pulmonary in Calu-3 cells and mouse models 48 . It has been reported that in the Vero E6 cell model, Remdesivir exhibits the effect of inhibiting the infection of 2019-nCoV virus, with the EC50 at 0.77 micrometers and the SI more than 129.87 34 . Since 2019-nCoV and MERS-CoV possess similar structure belonging to the coronavirus 2,8 , Remdesivir has a great potential of anti-2019-nCoV. As reported, the first case of new coronavirus pneumonia treated in the United States only received supportive treatment for nausea, vomiting and other symptoms at the initial stage of admission, while the patient's symptoms improved significantly after being given the intravenous injection of Remdesivir for one day 45 . However, Remdesivir has not 20 approved listed in any country, its safety and effectiveness must be confirmed. Thus , two randomized, controlled, double blind Phase III trials have been addressed in February 2020 (NCT04252664 and NCT04257656).
Ribavirin is a broad-spectrum antiviral nucleoside analogue which has been used in the treatment for HCV and RSV. The antiviral mechanism is interacting with virus RdRp to inhibit RNA synthesis 55 . In vitro experiments, it's shown that Ribavirin inhibits replication of MERS-CoV and HCoV-OC43, but the dosage that produces significant effects is not within the range of typical human therapies 59 . Using interferon simultaneously can reduce the dose of Ribavirin 60 . In a primate model, the clinical symptoms of MERS could be improved by the combination of Ribavirin and type I interferon 61 . However, the side effects of ribavirin, such as anemia, limit its widespread use 62 . In addition, two meta-analyses of SARS and MERS case studies exhibited limited efficacy in treating patients with coronavirus respiratory syndrome 63, 64 . Therefore, further studies are needed to determine whether ribavirin can effectively treat novel coronavirus pneumonia (COVID- 19) , and Ribavirin and interferon are still in clinical trials (ChiCT R2000029387).
Protease inhibitor
Lopinavir/Ritonavir (Kaletra/Aluvia) is a protease inhibitor used in combined therapy for HIV 65 . Lopinavir inhibits the decomposition of gag-pol protein, while Ritonavir inhibits the decomposition of gag-pol protein precursor and lopinavir metabolism to increase the concentration of Lopinavir 66 . It has been shown that Lopinavir/Ritonavir could inhibit replication of MERS-CoV and SARS-CoV in vitro. In primate models, animals treated with Lopinavir/Ritonavir for MERS have a better prognosis than those not treated 67 . A non-critical 2019-nCoV infected patient in South Korea received Lopinavir/Ritonavir (Kaletra, AbbVie) on the eighth day of admission, after which the clinical symptoms improved and the coronavirus load began to decrease until undetectable 68 . Animal models suggest that TMPRSS2 (type II transmembrane serine proteases)plays an important role in coronavirus transmission 69 . TMPRSS2 activates the S protein of highly pathogenic human coronavirus, which binds to ACE2 receptor and enters host cells 38, [69] [70] [71] [72] . Thus, TMPRSS2 inhibitors are also considered as drugs for the treatment of novel coronavirus pneumonia 73 .
Broad-spectrum antiviral
Interferon is a kind of glycoprotein and triggers the antiviral immune response in patients infected with virus 74 . In animal models, interferon inhibits the replication of SARS-CoV and MERS-CoV. In addition, combination therapies of interferon with other antiviral drugs have been used to treat SARS or MERS patients and show synergistic effects 60, 74 .
Chloroquine also has a strong antiviral effect on SARS-CoV infected cells. It interferes with virus-receptor binding by ACE2 terminal glycosylation 75, 76 . In vitro, chloroquine can enhance the effects of other antiviral drugs 34 .
Immunity therapy
Due to the similar RBD structures of 2019-nCoV and SARS-CoV, screening the anti-SARS-CoV antibodies will facilitate rapid development of monoclonal antibodies and vaccines against 2019-ncov 33 . Li et al. 33 reported that CR3022, SARS-CoV specific human 22 monoclonal antibody can effectively bind to 2019-nCoV RBD. CR3022 has the potential to be used alone or in combination with other neutralizing antibodies for the prevention and treatment of 2019-nCoV infection 33 . However, the dose of needs to be screened before applying monoclonal antibodies 77 . Using convalescent plasma to treat critically ill patients has been included by the latest Chinese treatment protocol (Pilot Version 6). One meta-analysis exhibits glucocorticoids reduces the risk of ARDS 78 . But different studies suggest that glucocorticoids slow viral clearance 79 . Clinical data are still needed to demonstrate the value of glucocorticoid use for 2019-nCoV 66 .
Other methods
Studies have shown that, similar to SARS-CoV, S protein receptor binding domain (RBD) of 2019-nCoV and human angiotensin conversion enzyme Ⅱ (ACE2), which is one of the reasons for the 2019-nCoV to infect humans 12, 33 . Zhou et al. 2 report that ACE2 is the receptor of 2019-nCoV through cell experiments: 2019-nCoV could bind ACE2 receptors of civet, bat, pig and human origin, and cannot infect cells without ACE2. Therefore, the application of ACEI and AT1R inhibitors under the condition of close monitoring of blood pressure is likely to reduce the body damage in patients with 2019-nCoV infection 80 . Xuebijing is a traditional Chinese medicine injection commonly used to treat inflammation in severe cases. A randomized controlled trial shows that on the basis of western medicine treatment, xuebijing injection could significantly reduce the fatality rate of community acquired pneumonia 81 .
Further reliable evidence needs accumulating as a potential Chinese medicine for COVID-19. 23 
Prevention
Traveler screening
Following its recent emergence, traveler screening is a way used to limit further spread of 2019-nCoV and the purpose is to curtail geographic spread of the infection 82 . The traveler symptom screening depends on the natural history of the infection. The individuals who were infected are likely to show detectable symptoms with the increasing time since exposure.
However, the traveler screening is also limited. Katelyn et al. 83 perform tests to estimate the effectiveness of traveler screening and they find within the narrow range of the tests, traveler screening outcomes are sensitive to the short incubation period mean. However, for the longer incubation periods, the larger proportions of departing travelers will not exhibit symptoms.
The point at long incubation periods they still feel healthy enough to travel and do not realize they have been exposed to 2019-nCoV which is simultaneously difficult to detect 84 .
Sesame oil
A folk method expresses that the adding of sesame oil into nostrils can prevent the spread of 2019-nCoV. In order to find the theoretical reasons to support this method for preventing viral infection of 2019-nCoV, Fan et al. 85 make discussions based on colloid and interface science pure and point out that sesame oil has a low surface tension and it is incompatible with water 86 . They investigate the epidemiological features of 2019-nCoV and find because of the low intermolecular attraction between adjacent two sesame oil molecules, the pure sesame oil has a good wettability which can readily wet the surface of various solid and aqueous phases. In view of this feature, the sesame oil might prevent the spread of 2019-nCoV. Unfortunately, the mechanism of this method remains uncertain and it is not approved and verified by experimental and clinical studies. In the future, scientists need to pay more scientific attention to these potential useful clues from the folk medical methods.
Natural compounds
Traditional Chinese medicine herbs have been practiced for thousand years. In 2003, glycyrrhizin, a traditional Chinese medicine, was suggested to be promising for treating SARS 87 and it was considered to be effective and a valuable pool for the availability and the low toxicity. Searching the active compounds from Chinese herbal medicine to prevent the 2019-nCoV could be a potential strategy. Chen et al. 88 used the molecular docking to find natural compounds, they proposed the five candidates including Scutellarin, baicalin, Hesperetin, Nicotianamine and glycyrrhizin which are the potential compounds targeting the ACE2 receptor and exert anti-virus effects to prevent 2019-nCoV infection.
Conclusion
2019-nCoV is driving China's urgent public health actions, as well as international concern. We collect the recent progress of 2019-nCoV in the hope of providing potential interventions. The spread is fast with increasing infected patients nationwide and the future development of the disease is unclear but the public should pay attention to the virus since it may be very contagious. 
